인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
피인용 0
초록·키워드
A2E, a major pyridinium bisretinoid component of retinal lipofuscin, functions as a photosensitizer that undergoes blue light-induced oxidation, contributing to oxidative stress in age-related macular degeneration (AMD). This study investigated whether lipophilic antioxidants and non-antioxidant hydrophobic molecules protect A2E primarily through reactive oxygen species (ROS) quenching, modulation of its local microenvironment, or both. A2E was irradiated with blue light in the presence or absence of hydrophobic additives: palmitic acid (PA), vitamin E, β-carotene, lutein, zeaxanthin, and zeaxanthin dipalmitate (ZDP). Fluorescence spectroscopy assessed photophysical changes. A2E degradation was quantified using reverse-phase LC-MS with optimized electrospray ionization, distinguishing actual A2E loss from fluorescence artifacts. All additives significantly reduced A2E degradation, with protection strongly correlated with hydrophobicity. ZDP preserved about 76% of A2E, and even non-antioxidant PA offered marked protection. Fluorescence spectra showed compound-specific emissions and, notably, increased A2E fluorescence intensity with a blue shift, particularly with ZDP and PA, suggesting enhanced co-localization in lipid-rich domains. These results reveal two complementary protective mechanisms: classical ROS scavenging by carotenoids and vitamin E, and microenvironment remodeling by highly lipophilic molecules like ZDP and PA. The microenvironmental remodeling effects of lipophilic compounds remain speculative and warrants further investigation. Thus, strategies targeting both ROS neutralization and A2E’s hydrophobic niche may effectively mitigate blue-light-driven retinal damage in AMD.
본문·목차
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
UCI(KEPA) : I410-151-26-02-096640698
